Grindr to Acquire Freddie (PurposeMed) for $250M — First Major Acquisition, Enters HIV Prevention Telehealth
GRND sits 58% above its 52-week low of $9.732.
Summary
Grindr agreed to acquire Freddie (PurposeMed), a PrEP/HIV prevention telehealth provider, for $250M upfront plus up to $70M in earnout — its first major acquisition and entry into healthcare.
Key Events · M&A and Partnerships · GRND
-
Acquires Freddie for $250M Upfront
Grindr will acquire PurposeMed Inc., parent of Freddie, for $250 million — $190M in cash and $60M in 3,851,684 shares of Grindr common stock valued at $15.58/share (15-day VWAP ending Sept 29, 2026), subject to a 12-month lock-up.
-
Up to $70M Earnout Tied to 2027 Targets
Additional cash consideration of up to $70M is payable in 2028 if Freddie achieves certain FY2027 financial performance targets.
-
Freddie Financial Profile
Freddie expects 2026 revenue above $80M and Adjusted EBITDA above $10M, with 25,000+ active patients as of end of September 2026. Grindr expects the acquisition to have an immaterial impact on 2026 results.
-
Strategic Entry into HIV Prevention
The deal integrates PrEP access directly into the Grindr app, targeting an estimated 2M+ additional US Grindr users who should be on PrEP. Grindr believes the healthcare business can eventually be as large as its core dating business.
Analysis · GRND · Technology
Grindr is making its first major acquisition since founding, buying PurposeMed — the parent of Freddie, a leading PrEP and HIV prevention telehealth provider — for $250 million upfront ($190M cash + $60M in stock) plus up to $70M in earnout. The deal transforms Grindr from a dating app into a healthcare platform, directly integrating PrEP access into the app used by millions of gay men. Freddie expects 2026 revenue above $80M and Adjusted EBITDA above $10M, with 25,000+ active patients. The stock consideration is priced at $15.58 per share (15-day VWAP ending Sept 29, 2026), slightly above today's $15.40 price. Closing is expected in Q4 2026, subject to restructuring, NYSE listing approval, and other conditions, with a termination right if not closed by December 30, 2026. This is a strategic expansion into a large, regulated healthcare market that Grindr believes can eventually be as large as its core business.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRND was trading at $15.40 on NYSE in the Technology sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $9.73 to $18.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.